Research outputs

@article{Hashimoto2026,

title = {Macular Atrophy in the Better-Seeing Eye of Australian Patients Treated for Neovascular Age-Related Macular Degeneration},

author = {Yohei Hashimoto and Ian Reddie and Zanne Louw and Mark Gillies},

doi = {10.1111/ceo.70032},

issn = {1442-9071},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {54},

number = {2},

pages = {295–297},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Gillies2026,

title = {Twelve-Month Real-World Outcomes of Faricimab for Treatment-Naive Neovascular AMD in Australia},

author = {Mark Gillies and Yohei Hashimoto and Rahman Nazari and Jennifer Arnold and Beibei Wang and Richard Barry and Ross Ferrier and Justin Game and Daniel Barthelmes},

doi = {10.1111/ceo.70072},

issn = {1442-9071},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {54},

number = {4},

pages = {500–506},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Dang2026,

title = {Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry},

author = {Trung M Dang and Alessandro Invernizzi and Vuong Nguyen and Yohei Hashimoto and Francesco Romano and Mariano Cozzi and Jennifer Arnold and James Wong and Hemal Mehta and Samantha Fraser-Bell and Richard Barry and Daniel Barthelmes and Mark Gillies and Alan Luckie},

doi = {10.1111/ceo.70033},

issn = {1442-9071},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {54},

number = {2},

pages = {233–240},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Rudolph2026,

title = {Five-Year Treatment Outcomes of Macular Oedema Secondary to Central Retinal Vein Occlusion in Routine Clinical Practice: The Fight Retinal Blindness! Registry},

author = {Katrin Rudolph and Marianna Rosso and Mark Gillies and Adrian Hunt and Louise O'Toole and Alessandro Invernizzi and David Squirrell and Hemal Mehta and Richard Barry and Pierre-Henry Gabrielle and Daniel Barthelmes},

doi = {10.1111/ceo.70164},

issn = {1442-9071},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Clinical and Experimental Ophthalmology},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hashimoto2026c,

title = {When Retention Becomes an Outcome: Disentangling Faricimab Durability and Care Access-Response},

author = {Yohei Hashimoto and Mark Gillies},

doi = {10.1111/ceo.70185},

issn = {1442-9071},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Clinical and Experimental Ophthalmology},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Teo2025,

title = {Progression of Loss of Vision From Centre-Involving Macular Atrophy in Eyes Treated for nAMD},

author = {Kelvin Y C Teo and Theodorus Leonardus Ponsioen and Sioe Lan and Louise O'Toole and Carolina Arruabarrena Sanchez and Richard Barry and Helena Brosa Morros and Charmaine Chung and Alessandro Invernizzi and Gemmy Chui Ming Cheung and Daniel Barthelmes and Mark C Gillies},

doi = {10.1111/ceo.14587},

issn = {1442-9071},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {53},

number = {8},

pages = {925–935},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hunt2025,

title = {Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry},

author = {Adrian Hunt and Yohei Hashimoto and Stephanie Young and Jennifer Arnold and Justin Game and Claire Hooper and Andrew Field and Richard Barry and Daniel Barthelmes and Mark Gillies},

doi = {10.1111/ceo.14589},

issn = {1442-9071},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {53},

number = {9},

pages = {1156–1167},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025,

title = {Association Between Prior Selective Laser Trabeculoplasty and Phaco-iStent Inject Efficacy},

author = {Jeremy C K Tan and Colin I Clement and Andrew White and Hamish Dunn and Bernardo Soares and David Wechsler and Vincent Lee and Mitchell Lawlor},

doi = {10.1111/ceo.14588},

issn = {1442-9071},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {53},

number = {9},

pages = {1148–1155},

keywords = {Clinical and Experimental Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Ponsioen2024,

title = {Outliers of Treatment Frequency in Retinal Vein Occlusion: 24‐Month Comparative Analysis of Fight Retinal Blindness! Practitioners},

author = {Theodorus Ponsioen and Yohei Hashimoto and Alessandro Invernizzi and Pierre‐Henry Gabrielle and Francisco Javier Lavid and Hemal Mehta and Rufino Silva and Nandor Jaross and David Squirrell and Louise O'Toole and Pavol Kusenda and Daniel Barthelmes and Mark Gillies and Adrian Hunt},

doi = {10.1111/ceo.14490},

issn = {1442-9071},

year  = {2024},

date = {2024-12-28},

urldate = {2024-12-28},

journal = {Clinical and Experimental Ophthalmology},

publisher = {Wiley},

abstract = {ABSTRACT Background We aimed to describe a 2‐year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO). Methods A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012–2022 tracked in the Fight Retinal Blindness! registry. Results We identified 3 outlying ‘intensive’ practitioners (managing 350/1110 eyes [32%]), 22 ‘typical’ practitioners (604/1110, [54%]) and 4 outlying ‘relaxed’ practitioners (156/1110, [14%]) with respective 24‐month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.2, +13.6, +9.3 letters ( p < 0.01) and CRVO: +14.2, +12.7, +4.8 letters ( p < 0.01); adjusted change in macular thickness in BRVO −179, −150, −159 μm ( p < 0.01) and CRVO −324, −283, −232 μm ( p < 0.01); time‐in‐range with VA > 68 letters in BRVO 90, 78, 68 weeks ( p < 0.01) and CRVO 69, 60, 54 weeks ( p = 0.04); median injections 18, 13 and 10; median final injection intervals, BRVO 6, 9, 10 weeks and CRVO 6, 9 and 12 weeks; with no significant difference in adverse outcomes. Conclusions At 24 months, the intensive practitioners were treating RVO using VEGF inhibitors with twice the frequency of the relaxed practitioners; however, their patients had gained twice (BRVO) to three times (CRVO) more letters of VA.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Invernizzi2024,

title = {Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion},

author = {Alessandro Invernizzi and Matteo Airaldi and Mariano Cozzi and Vuong Nguyen and Yohei Hashimoto and Daniel Barthelmes and Louise O'Toole and Theodorus Leonardus Ponsioen and Pavol Kusenda and Francisco Javier Lavid and Nandor Jaross and Mark Gillies and Adrian Hunt},

doi = {10.1111/ceo.14468},

issn = {1442-9071},

year  = {2024},

date = {2024-12-05},

urldate = {2024-12-05},

journal = {Clinical and Experimental Ophthalmology},

publisher = {Wiley},

abstract = {Background To assess clinical outcomes of cataract surgery in eyes treated with intravitreal injections for cystoid macular oedema (CMO) secondary to retinal vein occlusions (RVOs). Methods Eyes receiving intravitreal injections for CMO secondary to RVOs that underwent cataract extraction were identified from the Fight Retinal Blindness! Registry and matched 1:1 by 9 parameters with phakic controls also receiving intravitreal injections for the same condition. VA change at 12 months, central subfield thickness (CST) and injection frequency before and after surgery were compared between the two groups. The effect of baseline features on the final VA including age, CST, treatment frequency among others was tested. Results We included 193 eyes that had cataract extraction (exposed) matched with 193 phakic eyes that did not have surgery (matched). VA (95%CI) changed by +9.9 (7, 12.8) letters in exposed eyes versus −2.4 (−4.1, −0.7) letters in matched eyes ( p < 0.01). The mean [SD] VA at 12 months was similar in exposed and matched eyes [60.7 (23.0) vs. 61.1 (24.3) letters, respectively},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Airaldi2023,

title = {Twenty‐four‐month real‐life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians},

author = {Matteo Airaldi and Alessandro Invernizzi and Vuong Nguyen and Stela Vujosevic and Federico Ricci and Pietro Monaco and Marco Nassisi and Daniel Barthelmes and Mark Gillies and Francesco Viola},

doi = {10.1111/ceo.14305},

issn = {1442-9071},

year  = {2023},

date = {2023-11-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {51},

number = {8},

pages = {799–807},

publisher = {Wiley},

abstract = {Background To compare 24‐month real‐world outcomes of Vascular Endothelial Growth Factor (VEGF) inhibitors for Polypoidal Choroidal Vasculopathy (PCV) and type 1 Macular Neovascularization (MNV) in a Caucasian population. Methods Retrospective analysis from a prospectively designed observational database. Data from Italian centres participating in the Fight Retinal Blindness! (FRB!) project were collected. Treatment‐naïve PCV or type 1 MNV commencing treatment after January 2009 were included. The primary outcome was 24‐month visual acuity (VA) change; other outcomes included baseline characteristics, number of anti‐VEGF injections, time to lesion inactivation and proportion of active visits. Results A total of 322 eyes (114 PCVs) from 291 patients were included. Median [Q1, Q3] VA at baseline was comparable (70 [55, 75.8] vs. 70 [58.8, 75] letters},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Kandel2023b,

title = {Opportunities and challenges for clinical registries},

author = {Himal Kandel and Mark C. Gillies and Stephanie L. Watson},

doi = {10.1111/ceo.14260},

issn = {1442-9071},

year  = {2023},

date = {2023-08-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {51},

number = {6},

pages = {651–652},

publisher = {Wiley},

keywords = {Clinical and Experimental Ophthalmology, Fight Corneal Blindness, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Ferdi2022,

title = {Five‐year corneal cross‐linking outcomes: A Save Sight Keratoconus Registry Study},

author = {Alex C. Ferdi and Himal Kandel and Vuong Nguyen and Jeremy Tan and Francisco Arnalich‐Montiel and Marco Abbondanza and Stephanie L. Watson},

doi = {10.1111/ceo.14177},

issn = {1442-9071},

year  = {2023},

date = {2023-01-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {51},

number = {1},

pages = {9–18},

publisher = {Wiley},

abstract = {Background We aimed to determine the long‐term outcomes of epithelium‐off cross‐linking (CXL) in keratoconus patients. Methods An observational registry study from 41 centres across 5 countries was carried out. Primary outcomes included the mean change in visual acuity (VA), Kmax, K2, and thinnest corneal thickness (TCT) at 1–5 years. Secondary outcomes included the percentage of eyes with worsening, stable and improving outcomes. Results There were 976 eyes of 794 patients with 1‐year of complete follow‐up, 501 eyes with 2‐years, 355 with 3‐years, 235 with 4‐years and 162 with 5‐years. There was a significant improvement in mean VA from baseline by 3.7 logMAR letters ( p < 0.001) in year 1, and 6.9 ( p < 0.001) in year 5. Mean Kmax decreased by 1.2 dioptres (D; p < 0.01) in year 1. During subsequent years the Kmax flattening appeared sustained but this was not statistically significant. K2 flattened significantly from baseline in year 1 and then remained stable. At 1 year, 4.1% patients were poor responders to CXL in terms of VA, losing ≥15 letters. The proportion of the poor responders remained unchanged: 4.9% at 5‐years. The proportion of poor responders in terms of Kmax remained similar: 5.9% steepening by ≥2D at 1‐year and 7.5% at 5‐years. The proportion of K2 poor responders remained stable with 4.7% steepening by ≥2D at 1‐year and 5.8% at 5‐years. Conclusions Cross‐linking is effective at stabilising keratoconus up to 5 years in most patients. However, a small proportion of eyes failed to stabilise and had reduced vision.},

keywords = {Clinical and Experimental Ophthalmology, Fight Corneal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Wang2022,

title = {One‐year real‐world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion},

author = {Nancy Wang and Adrian Hunt and Vuong Nguyen and Janika Shah and Samantha Fraser‐Bell and Ian McAllister and Daniel Barthelmes and Mark Gillies and David Squirrell},

doi = {10.1111/ceo.14139},

issn = {1442-9071},

year  = {2022},

date = {2022-12-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {50},

number = {9},

pages = {1038–1046},

publisher = {Wiley},

abstract = {Background Bevacizumab is the only agent that many people can afford, yet there are only limited data on whether it improves macular oedema (MO) secondary to retinal vein occlusion (RVO) in real‐world clinical practice. Here we studied 12‐month real‐world treatment outcomes of bevacizumab for RVO‐related MO. Methods This was a multicentre, observational study analysing 12‐month data from the Fight Retinal Blindness! (FRB) database. We studied treatment‐naïve eyes with MO secondary to RVO commencing bevacizumab therapy between June 2009 and June 2019. Visual acuity (VA) and central subfield thickness (CST) were measured at baseline, 6 and 12 months. The primary outcome was a change in VA from baseline to 12 months. Results Two hundred and twenty treatment naive eyes were analyzed. The baseline VA for BRVO was better than CRVO (55.8 vs. 42.6 LogMAR letters) and this gap widened over the 12‐month period, with a 12‐month VA change of +14.0 (95% CI 11.1, 16.8) letters for BRVO and + 11.9 (95% CI 6.4, 17.4) for CRVO. The mean CST at baseline was 511 μm for BRVO and 627 μm for CRVO, falling at 12 months by −155 μm (−190, −121) in BRVO and −198 μm (−252, −145) in CRVO. The median number of injections for BRVO and CRVO completers was 7 (5, 9). Conclusions Bevacizumab can be an effective treatment of RVO‐MO in a real‐world setting with outcomes approaching those reported by the seminal clinical trials. The functional and anatomical outcomes of intravitreal therapy were better for BRVO than CRVO.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Kandel2022c,

title = {Quality of life impact of eye diseases: a Save Sight Registries study},

author = {Himal Kandel and Vuong Nguyen and Stefano Piermarocchi and Lala Ceklic and Kelvin Teo and Francisco Arnalich‐Montiel and Stefania Miotto and Vincent Daien and Mark C. Gillies and Stephanie L. Watson},

doi = {10.1111/ceo.14050},

issn = {1442-9071},

year  = {2022},

date = {2022-05-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {50},

number = {4},

pages = {386–397},

publisher = {Wiley},

abstract = {Background The objectives of this study were to evaluate the quality‐of‐life (QoL) impact of eye diseases (keratoconus; neovascular age‐related macular degeneration, AMD; retinal vein occlusion, RVO; and diabetic macular edema, DME) using the Impact of Vision Impairment (IVI) questionnaire, and to determine the relationship between the IVI scores and visual acuity. Methods This cross‐sectional, multicentre, real‐world study utilised the prospective, web‐based Save Sight Registries. The IVI was completed by 1557 patients: 307 with keratoconus, 1049 with AMD, 148 with RVO and 53 with DME. Statistical analysis included Rasch analysis, Welch t ‐test, one‐way ANOVA, Tukey's test, Pearson correlation, and multiple regression. Results The IVI scales (Overall; Visual Function, VF; Emotional, EM) had robust psychometric properties. The keratoconus patients had the worst Overall (adjusted mean: 48.2 vs. DME 58.8, RVO 64.6, AMD 67.6 units), VF (47.7 vs. DME 59.4, RVO 65.9, AMD 68.9 units) and EM (50.8 vs. DME 63.1, RVO 69.2, AMD 71.8 units) scores (all p < 0.05). The IVI scales scores weakly correlated with better and worse eye visual acuity (Pearson's r 0.24–0.39, all p < 0.05). The correlations were similar in the better eye (Overall 0.35, VF 0.39, EM 0.24) and the worse eye (Overall 0.31, VF 0.33, EM 0.25) visual acuity. Correlations with visual acuity were stronger for VF than for the EM scores. Conclusions The IVI was a psychometrically robust QoL questionnaire. Keratoconus patients had worse IVI scores than patients with retinal diseases. The low strength of correlations between visual acuity and QoL scores, although statistically significant, suggested that a complex relationship exists.},

keywords = {Clinical and Experimental Ophthalmology, Fight Corneal Blindness, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Holmes2022,

title = {Comparative study of 2‐year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery},

author = {David P. Holmes and Colin I. Clement and Vuong Nguyen and Paul R. Healey and Ridia Lim and Andrew White and Joshua Yuen and Mitchell Lawlor},

doi = {10.1111/ceo.14048},

issn = {1442-9071},

year  = {2022},

date = {2022-04-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {50},

number = {3},

pages = {303–311},

publisher = {Wiley},

abstract = {Background To compare real‐world 24‐month outcomes of phacoemulsification combined with either iStent inject or Hydrus Microstent. Methods Analysis of data from the Fight Glaucoma Blindness (FGB) international registry. Anonymized data from 344 eyes with mild‐to‐moderate open‐angle glaucoma, normal‐tension glaucoma or ocular hypertension that underwent phacoemulsification combined with either iStent inject (224) or Hydrus Microstent (120) were included. Data were adjusted for baseline characteristics using linear regression and propensity score matching. The primary endpoint was a comparison of mean intraocular pressure (IOP) at 24 months. Results At 24 months, there was no significant difference in IOP reduction between the two groups, consistent across all analyses. The matched cohort showed iStent inject achieved 3.1 mmHg reduction and Hydrus a 2.3 mmHg reduction ( p = 0.530) and a mean medication reduction of 1.0 for iStent inject versus 0.5 for Hydrus ( p = 0.081). 5.4% of eyes in the iStent inject group and 7.5% of eyes in the Hydrus group required subsequent procedures to improve IOP control within 24 months. Complications were rare with no significant differences between the groups. Conclusions Twenty‐four‐month outcomes showed sustained IOP reduction with a good safety profile for both groups. There was no significant difference in IOP outcomes between the groups. There may be a small additional reduction in glaucoma medication usage following cataract surgery with iStent inject compared to Hydrus.},

keywords = {Clinical and Experimental Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Zarranz‐Ventura2022,

title = {Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes},

author = {Javier Zarranz‐Ventura and Alba Parrado‐Carrillo and Vuong Nguyen and Laura Sararols and Gonzaga Garay‐Aramburu and Martín Puzo and Carolina Arruabarrena and Marc Figueras‐Roca and Mark C. Gillies and Ricardo P. Casaroli‐Marano and},

doi = {10.1111/ceo.14054},

issn = {1442-9071},

year  = {2022},

date = {2022-04-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {50},

number = {3},

pages = {312–324},

publisher = {Wiley},

abstract = {Background To study the visual outcomes of neovascular AMD (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) drugs at national level. Methods Multicenter national database of nAMD eyes treated with anti‐VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat‐and‐extend (TAE) regimens. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) ETDRS letters at baseline and subsequent visits, number of injections and visits data were collected using a validated web‐based tool (Fight Retinal Blindness!). Results 1273 eyes (1014 patients) were included, 971 treatment naïve (TN) and 302 previously treated (PT). Baseline VA (mean ± SD) was 57.5 (±19.5) and 62.2 (±17) ( p > 0.001), and 24 months final VA was 60.4 (±21.2) and 58.8 (±21.1) ( p = 0.326), respectively. Mean VA change at 12/24 months was +4.2/+2.9 letters in TN eyes and +0.1/−3.4 letters in PT eyes ( p < 0.001/ p < 0.001). The percentage of ≥15 letters gainers/losers at 24 months was 24.8%/14.5% in TN, and 10.3%/15.7% in PT eyes. The median number of injections/visits at 12 months was 7/9 in TN and 6/8 in PT ( p = 0.002/ p < 0.001) and at 24 months was 11/16 in TN and 11/14 in PT ( p = 0.329/ p < 0.001). Study drugs included ranibizumab (39.5%), aflibercept (41.2%) and bevacizumab (19.3%). Conclusion Independent, large‐scale national audits are feasible if committed health care professionals are provided with efficient information technology systems to do them. The results described here represent an adequate measurement of the quality of care delivered nationwide and benchmark the clinical management of nAMD at a country level compared to other real‐world international cohorts.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Nguyen2021,

title = {Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry},

author = {Vuong Nguyen and Daniel Barthelmes and Mark C. Gillies},

doi = {10.1111/ceo.13949},

issn = {1442-9071},

year  = {2021},

date = {2021-09-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {49},

number = {7},

pages = {652–663},

publisher = {Wiley},

abstract = {The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of neovascular age‐related macular degeneration (nAMD) since the pivotal Phase III studies demonstrated their efficacy more than 10 years ago. The Fight Retinal Blindness! project was developed to track the treatment outcomes of patients with nAMD in real‐world practice. Data from this registry have been used to answer several clinically relevant questions related to the treatment of nAMD including the effect of under‐treatment, the comparative effectiveness of different anti‐vascular endothelial growth factor agents, long‐term treatment outcomes, identifying optimal treatment regimens and the rate and outcomes of rare adverse events. Observational studies are a valuable complement to the shortcomings of clinical trials and a combination of data from real‐world settings and clinical trials are necessary to provide evidence on how to achieve the best outcomes for individual patients with nAMD.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Cornish2021,

title = {Neovascular age‐related macular degeneration at treatment intervals of 14 weeks or greater},

author = {Elisa E. Cornish and Vuong Nguyen and Stephanie Young and Samantha Fraser‐Bell and Robyn Guymer and David Squirrell and Daniel Barthelmes and Mark C. Gillies},

doi = {10.1111/ceo.13962},

issn = {1442-9071},

year  = {2021},

date = {2021-08-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {49},

number = {6},

pages = {570–578},

publisher = {Wiley},

abstract = {Background We assessed the proportion of eyes with neovascular age‐related macular degeneration (nAMD) in routine clinical practice that reach ≥14 week treatment intervals and their outcomes. Method We analysed data from the Fight Retinal Blindness! (FRB!) Project database, a prospectively designed registry of ‘real‐world’ outcomes. Treatment‐naive eyes starting vascular endothelial growth factor (VEGF) inhibitors for nAMD from 1st January 2006 were included. Eyes were defined to have reached the ≥14 week treatment interval if they received ≥2 consecutive injections at treatment intervals of ≥14 week but not exceeding 26 weeks. Outcomes were reported in a subgroup of eyes that had 12 months of follow‐up from reaching this interval. Results Of the 3907 treatment‐naïve eyes that started treatment during the identified periods on a treat‐and‐extend regimen and received at least 8 injections over the first 2 years, 402 (10%) eyes received at least 2 consecutive injections at an interval of ≥14 week during their follow‐up. Fifty‐two percent of these eyes maintained vision to 12 months, however only 40% stayed at this interval and 25% of the lesions reactivated. Conclusion We found that only 10% of eyes with nAMD were extended beyond a 13‐week injection interval and that over half had returned to a shorter interval by 12 months. Eyes that stayed at this extended treatment interval maintained stable vision. More data on the outcomes of eyes treated with intervals longer than 3 months are required to establish whether emerging VEGF inhibitors provide a more sustained effect than the currently available drugs.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Wiryasaputra2020,

title = {Four‐week outcomes of vascular endothelial growth factor inhibitors for neovascular age‐related macular degeneration},

author = {Shaan Wiryasaputra and Vuong Nguyen and Jennifer J. Arnold and Ross Ferrier and Peter Hinchcliffe and Daniel Barthelmes and Mark C. Gillies},

doi = {10.1111/ceo.13798},

issn = {1442-9071},

year  = {2020},

date = {2020-09-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {48},

number = {7},

pages = {946–955},

publisher = {Wiley},

abstract = {Importance To assess early outcomes of intravitreal vascular endothelial growth factor (VEGF) inhibitor treatment in neovascular age‐related macular degeneration (nAMD) before patients have a chance to miss or discontinue treatment. Background Intravitreal VEGF inhibitors used to treat nAMD have been compared in various ways. The present study compared the 4‐week responses to the first injection of either aflibercept, bevacizumab, or ranibizumab. Design Observational study. Participants Treatment‐naïve nAMD patients with visual acuity (VA) taken 22 to 48 days after the first treatment with an intravitreal VEGF inhibitor. Methods An observational study from a prospectively designed database. Main outcome measures VA change from baseline and proportion of eyes judged active 22 to 48 days after the first treatment. Results The overall mean (95% confidence interval [CI]) VA change at 4 weeks was +3.7 (3.3, 4.0) letters. No pairwise comparisons in crude VA change or VA change after multivariate adjustment between the three agents were significant. However, after multivariate adjustment, more eyes treated with bevacizumab (90%) had active disease 4 weeks after the first injection than ranibizumab (84%; P = .013) and aflibercept (82%; P = .004). Older age, higher baseline vision and larger lesions were associated with lower VA change. Conclusion There was no significant difference in VA gains amongst all three drugs but ranibizumab and aflibercept seemed to be more efficacious in quelling disease activity 4 weeks after the first treatment. VA change after the first injection was driven largely by baseline characteristics such as age, baseline VA and lesion size.},

keywords = {Clinical and Experimental Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}